Eplontersen trial fails to meet primary endpoint in transthyretin-mediated amyloid cardiomyopathy

The CARDIO-TTRansform trial investigating eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, according to results presented in a Hot Line session at ESC Congress 2026.

Raccontata damedicalxpress.com